Cargando…
Antiplatelet drugs block platelet activation by VITT patient serum
Autores principales: | Smith, Christopher W., Montague, Samantha J., Kardeby, Caroline, Di, Ying, Lowe, Gillian C., Lester, William A., Watson, Steve P., Nicolson, Phillip L. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8697531/ https://www.ncbi.nlm.nih.gov/pubmed/34375398 http://dx.doi.org/10.1182/blood.2021012277 |
Ejemplares similares
-
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT
por: Kanack, Adam J., et al.
Publicado: (2022) -
Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021) -
Understanding VITT(ual) reality
por: Rauova, Lubica, et al.
Publicado: (2021) -
VITT(al) insights into vaccine-related clots
por: Strich, Jeffrey R., et al.
Publicado: (2021) -
Anti‐platelet factor 4 immunoglobulin G levels in vaccine‐induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months
por: Montague, Samantha J., et al.
Publicado: (2022)